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Abstract. Artificial Intelligence (AI) technology is based on theory and development of computer 
systems able to perform tasks that normally require human intelligence. In this context, deep learning is 
a family of computational methods that allow an algorithm to program itself by learning from a large 
set of examples that demonstrate the desired behavior. Application of these methods to medical 
imaging can assist pathologists in the detection of cancer subtype, gene mutations and/or metastases for 
applying appropriate therapies. The purpose of this study is to show the emerging application of AI in 
medical imaging to detect lung and breast cancer. Moreover, this study shows the comparative 
evolutionary pathways of this emerging technology for three critical cancers: lung, breast and thyroid. 
A main finding of this study is the recognition that, since the late 1990, the sharp increase of 
technological trajectories of AI technology applied in cancer imaging seems to be driven by high rates 
of mortality of some types of cancer (e.g., lung and breast) in order to find new techniques for a more 
accurate detection, characterization and monitoring as well as to apply efficiently anticancer therapies 
that increase the progression-free survival of patients: the so-called mortality-driven AI technological 
trajectories. Results also suggest that this new technology can generate a technological paradigm shift 
for diagnostic assessment of any cancer type. However, application of these methods to medical 
imaging requires further assessment and validation to assist pathologists to increase the efficiency of 
their workflow in both routine tasks and critical cases of diagnostics. 
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Introduction 
Artificial Intelligence (AI) is the research field that studies and develops technological systems that can 
solve complex tasks in ways that would traditionally need human intelligence (Iafrate, 2018). This new 
technology, originated from interaction between engineering, computer science and other applied 
sciences, is developing main fields of applied research with technology transfer in robotics, natural 
language processing, machine learning, computer vision, etc. The artificial intelligence can be the 
source of a self-propagating development of technology that acquiring new functionality from digital 
industry and information and communication technology, it can generate a vast industrial and social 
change in economic systems (cf., Geuna et al., 2017). In this domain of AI, Machine Learning (ML) 
has made a tremendous progress over the last decades. Many scholars believe that ML is capable of 
making progress on any real-world problem. In the research field of machine learning, deep learning is 
a family of computational methods that allow an algorithm to program itself by learning from a large 
set of examples that demonstrate the desired behavior, removing the need to specify rules explicitly 
(cf., Goodfellow et al., 2018).   
In this context, the paper here shows the first applications of AI technology to cancer imaging that can 
generate a technological paradigm shift in oncology for improving diagnostics and accelerating 
treatments of these diseases (cf., Kantarjian and Yu, 2015; Li et al., 2019). This study focused on case 
studies of new deep learning algorithms for detection of lung and breast cancer that are two of the most 
important diseases in society. These case studies can show the high potential of path-breaking 
applications of AI in medicine that can generate an industrial and social change in clinics. Moreover, 
this study analyses the comparative evolutionary pathways of this emerging technology for three 
critical cancers (lung, breast and thyroid) to explain possible drivers. A discussion shows 
socioeconomic barriers to the diffusion of this new technology in medicine that can be generalized for 
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explaining the dynamics of this new technology in medicine and next applications in other sectors of 
economic system. 
Background 
Artificial Intelligence (AI) is the research field that studies and develops technological systems that can 
solve complex tasks in ways that would traditionally need human intelligence. The artificial 
intelligence can generate a vast industrial and social change in economic systems (cf., Geuna et al., 
2017).  
In this domain of AI, Machine learning (ML) is the scientific study of algorithms and statistical models 
that computer systems use to effectively perform a specific task without using explicit instructions, 
relying on patterns and inference instead (Fig. 1). Machine learning algorithms build a mathematical 
model based on sample data, known as "training data", in order to make predictions or decisions 
without being explicitly programmed to perform the task.     
Deep learning is part of a broader family of machine learning methods based on artificial neural 
networks (Madabhushi et al., 2016). Deep learning architectures such as deep neural networks, deep 
belief networks, recurrent neural networks and convolutional neural networks have been applied to 
fields including computer vision, speech recognition, natural language processing, audio recognition, 
social network filtering, machine translation, bioinformatics, drug design, medical image analysis, 
histopathological diagnosis, material inspection and board game programs, where they have produced 
results comparable to and in some cases superior to human experts (Litjens et al., 2016).  
This new technology, in particular, deep learning algorithms can be applied for improving diagnostic 
accuracy and efficiency of detection of cancer.   
4 
 
 
Figure 1. Artificial Intelligence and it main research fields 
Cancer is an organism which lives off a host organ, growing by bio-genetic-molecular mechanism. 9.6 
million people died of cancer in 2018 – more than from HIV/AIDS, malaria and tuberculosis 
combined. The incidence of cancer is estimated to double by 2035, with most of these cases expected to 
occur in low-to-middle income countries (LMICs). 60% of cancer cases occur in LMICs, and 75% 
cancer deaths occur in these countries (Prager, 2018). In many LMICs, breast cancer remains the 
leading malignancy affecting women and the leading cause of cancer-related deaths (Bray et al., 2018).  
Table 1 shows that lung and breast cancer have the highest mortality rate worldwide (cf. also Parkin et 
al., 2005; Coccia, 2015).  
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Table 1. Incidence and mortality of big 8 cancers in 2018, worldwide, both sexes, all ages 
Cancer 
Incidence Mortality 
ASR (W)* ASR (W)* 
 Lung 22.5 18.6 
 Breast 46.3 13.0 
 Colorectum 19.7 8.9 
 Prostate 29.3 7.6 
 Stomach 11.1 8.2 
 Pancreas 4.8 4.4 
 Ovary 7.8 3.9 
 Liver 9.3 8.5 
Note: Age-Standardized Rate-ASR (W): A rate is 
the number of new cases or deaths per 100,000 
persons per year. An age-standardized rate is the 
rate that a population would have if it had a 
standard age structure.  
Source. World Health Organization, International 
Agency for Research on Cancer (2019).  
 
The R&D in oncology is  supporting the convergence of different research fields, such as genetics1, 
genomics2, nanotechnology, nanomedicine, computer sciences, etc., that are generating new 
technological pathways for diagnostics and therapeutics (Coccia, 2014, 2015a, 2016, 2018). Clinical 
challenges are in the accurate detection and characterization of cancers. In particular, artificial 
intelligence (AI), generated by converging technologies in applied sciences, can support the qualitative 
interpretation of cancer imaging by expert clinicians, such as volumetric delineation of tumors as well 
as evaluation of the impact of disease and treatment on adjacent organs. In general, AI may automate 
                                                          
1  Genetics studies the molecular structure and function of genes in the context of a cell or organism. 
2  Genomics is a discipline in genetics that studies the genomes of organisms. In particular, it determines the entire DNA 
sequence of organisms and fine-scale genetic mapping efforts. 
6 
 
processes in the initial interpretation of images and shift the clinical workflow on high-level decisions 
to efficiently apply anti-cancer treatments for patients.  
The goal of this investigation  
The purpose of this study is to show the potential of Artificial Intelligence Technology in cancer 
imaging to distinguish between cancer, metastases or normal lung tissue. This study shows two case 
study of clinical challenges and applications of AI in lung and breast cancer. Moreover, this study 
endeavors to analyze evolutionary pathways of this AI for three critical cancers (lung, breast and 
thyroid) to explain possible drivers.  
Importance 
Importance of the paper here is to show that this emerging technology applied in medicine shows 
increasingly concerted efforts in pushing AI technology to clinical use and to impact future directions 
in cancer care, although most studies evaluating AI applications in oncology to medical imaging 
requires further assessment and validation for reproducibility and generalizability of results. 
Material and Methods: Study design and setting 
In order to show the potential of deep learning algorithms in cancer imaging, this study describes two case studies 
of AI technology applied for detection and characterization of lung cancer and lymph node metastases in women 
breast cancer.  
Moreover, to show the evolutionary pathways of AI technology and deep learning in the research field of cancer, 
this study considers data from ScienceDirect (2019) using the tool Advanced Search to find articles that have in 
title, abstract or keyword the following terms: 
 Artificial intelligence and lung cancer 
 Artificial intelligence and breast cancer 
 Artificial intelligence and thyroid cancer 
 Deep learning and lung cancer 
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 Deep learning and breast cancer 
 Deep learning and thyroid cancer 
The evolution of AI technology in cancer settings is measured with the number of articles from 1996 to 2018 for a 
comparative analysis of the trends of three different types of cancer (lung, breast and thyroid). The visual 
representation of trends is also used to detect the most appropriate model to estimate the relation of number of 
articles over time and assess the evolutionary growth of this new technology between different research fields of 
oncology (cf., Coccia, 2005, 2018a, 2019). 
The relation between number of articles per years of AI applied in cancer imaging of different cancers is estimated 
with regression analysis (Ordinary Least Squares Method) using an exponential model. Outputs of statistical 
analysis are:  regression coefficients, adjusted R2, standard error of the estimate and analysis-of-variance table. 
In order to assess the evolutionary growth of AI technology applied to specific types of cancer (lung, breast and 
thyroid cancer) the following exponential equation is applied over 1996-2018 period: 
𝑃𝑡(2018)=𝑃0(1996) 𝑒
𝑟𝑡  
P= number of articles with a combination of keywords 
𝑃𝑡
𝑃0
 =𝑒𝑟𝑡  
𝐿𝑜𝑔 (
𝑃𝑡
𝑃0
) =𝑟 ∙ 𝑡   
𝒓 =  
𝑳𝒐𝒈(
𝑷𝒕
𝑷𝟎
)
𝒕
   
A comparative analysis of results can suggest the direction and intensity of acceleration of 
technological trajectories of AI technology in different cancer settings and possible drivers. 
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Results: case studies and evolution of AI technology in cancer imaging 
 Artificial Intelligence and deep learning for detecting the typology of lung cancer: a revolution in 
medicine 
Lung cancer is one of the main diseases in several countries and a leading cause of cancer death – both 
sexes – worldwide. Lung cancer is linked to several risk factors in society, such as smoking, passive 
smoking, air pollution, etc. Lung cancer can be either small cell lung cancer or no small cell lung 
cancer (NSCLC), with the latter representing about 80% of the cases. The mortality of lung cancer is 
very high and the five-year survival rate of patients is about 2–10% (Coccia, 2014, 2012). The 
detection of the type of lung cancer (e.g., adenocarcinoma, squamous cell carcinoma, etc.), mutations 
(e.g., EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma receptor tyrosine kinase 
rearrangements) and sequential mutations (T790) is a critical process in diagnostics to select the 
appropriate therapy that can be conventional chemotherapies, target therapies such as gefitinib, 
erlotinib, etc., or new immune therapies, e.g., nivolumab, atezolizumab (cf., Coccia, 2014). This critical 
process affects the survival of patients (cf., Fig. 2).  
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Figure 2. Roadmap for Non-small lung cancer treatments based on EGF-R blocking agents. Source: 
Dempke et al. (2010), Lung Cancer, 67, p. 265  
 
Classification and mutation of lung cancer type is a critical diagnostic process because the available 
treatment options, including conventional chemotherapy and, more recently, targeted therapies, differ 
for lung adenocarcinoma and lung squamous cell carcinomas.  
Current technology for an accurate diagnosis and selection of treatment options is based on molecular 
biomarkers applied on lung biopsies and/or blood testing: this approach can diagnose lung cancer type 
and stage. This current technology has some negative effects. On the one side, patients have to receive 
an invasive surgical intervention for tissue biopsies or to do liquid biopsy (e.g., blood) and wait a 
certain time (about a month) before to have the diagnosis of cancer type and correct treatments, and the 
time in the presence of cancer is a critical variable for survival and, when possible, for healing. On the 
other side, hospitals have a high cost with these approaches that require appropriate equipment and 
specialized personnel, which in some regions are scarce or overload of work because of shrinking 
public lab and hospital budgets.  
New technology is based on artificial intelligence technology and some studies show that deep learning 
can be used for the classification of breast, bladder and lung tumors (Khosravi et al., 2018). In 
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particular, the development of new, inexpensive and more powerful artificial intelligence technologies 
has made possible the training of larger and more complex neural networks. This has resulted in the 
design of several deep convolutional neural networks (CNNs) that are capable of accomplishing 
complex visual recognition tasks. Coudray et al. (2018) show that medicine can benefit from deep 
learning technology by convolutional neural networks (CNNs) that not only outperforms other 
methods, but also achieves accuracies to classify the type of cancer that are comparable to pathologists 
for selecting the appropriate therapy. These models maintain their performance when tested on 
independent datasets of frozen tissues as well as on images obtained from biopsies. CNNs have been 
applied with regard to classification of lung patterns on computerized tomography (CT) scans, with 
positive results. This new technology is due to Google Corporation that in 2014 won the ImageNet 
Large-Scale Visual Recognition Challenge. The ImageNet project is a large visual database designed 
for use in visual object recognition software research. More than 14 million images have been hand-
annotated by the project to indicate what objects are pictured and in at least one million of the images, 
bounding boxes are also provided. ImageNet, developing the GoogleNet architecture, increased the 
robustness to translation and nonlinear learning abilities by using microarchitecture units called 
inception. Each inception unit includes several nonlinear convolution modules at various resolutions 
(cf., Russakovsky et al., 2015). Inception architecture is particularly useful for processing the data in 
multiple resolutions, a feature that makes this architecture suitable for medicine and in particular for 
pathology tasks. This complex neural network has already been successfully adapted to specific types 
of disease classifications like, skin cancers and diabetic retinopathy detection (Esteva et al., 2016; 
Gulshan et al., 2016). Coudray et al. (2018) have developed a deep-learning model for the automatic 
analysis of tumor slides using publicly available whole-slide images available in The Cancer Genome 
Atlas (TCGA). These scholars trained inception v3 to recognize tumor in lung versus normal tissue. 
After that, they tested the performance of these methods on the more challenging task of distinguishing 
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lung adenocarcinoma and lung squamous cell carcinoma. They also evaluated the deep-learning model 
by training and testing the network on a direct three-way classification into the three types of images 
(normal tissue, lung adenocarcinoma, lung squamous cell carcinoma). Results of this approach are 
compared to the evaluation of three pathologists (two thoracic pathologists and one anatomic 
pathologist) that independently classify the whole-slide images in the test set by visual inspection 
alone, independently of the classification provided by TCGA. Overall, the performance of deep 
learning models was comparable to that of each pathologist. Hence, new artificial intelligence 
technology, based on deep-learning models, can assist pathologists in the detection of cancer subtype or 
gene mutations in any cancer type with a save of time and costs; moreover, poor regions, with these AI 
technologies, can also have high benefits by sending the digital images to labs of other countries, 
generating a reduction of current gap in healthcare between countries. 
 Deep learning for detection of metastases in women with breast cancer 
Breast cancer is the most frequent cancer worldwide among women (see tab. 1). Studies based on 
advanced countries show that the incidence of breast cancer has been increasing. It has been postulated 
that breast cancer incidence tends to be higher in more developed countries due to delayed 
childbearing, a higher use of hormone replacement therapy, a higher rate of screening, and improved 
tumor registries. Some studies have also argued that higher income countries may have higher fat diets 
and an increased rate of obesity, both correlated with higher breast cancer incidence rates. In general, 
scholars note that many Western populations have a higher incidence rate of breast cancer than regions 
in Africa and Asia (Coccia, 2013).  
Breast biopsies, like all types of cancer, are used to diagnose breast cancer type, stage and mutations. 
An accurate breast cancer staging is an essential task performed by pathologists to inform clinical 
management. For instance, evaluation of the extent of cancer spread by histopathological analysis of 
sentinel axillary lymph nodes is an important part of breast cancer staging. The sensitivity of sentinel 
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axillary lymph nodes evaluation by pathologists, however, is sub-optimal because some studies show 
that pathology review by experts changed the nodal status in 24% of patients (Ehteshami Bejnordi et 
al., 2017). This effect is due to the difficulty of the process of decision making of human behavior. 
Moreover, sentinel axillary lymph nodes evaluation is time-consuming and has a certain cost. In short, 
the high cost of exams and a period of more than one month to have breast cancer type, stage, etc. to 
decide the appropriate therapy, it can affect results of therapeutic treatments and survival of patients.  
The application of Artificial Intelligence (AI) technology with deep learning algorithms to whole-slide 
pathology images can potentially improve diagnostic accuracy of breast cancer and metastases (Lamy 
et al., 2019). Some scholars have assessed the performance of automated deep learning algorithms at 
detecting metastases in tissue sections of lymph nodes of women with breast cancer and compared 
results with pathologists’ diagnoses. In the setting of a challenge competition, some deep learning 
algorithms achieved better diagnostic performance than a panel of 11 pathologists participating in a 
simulation exercise designed to mimic routine pathology workflow; in short, algorithm performance 
was comparable with an expert pathologist interpreting whole-slide images without time constraints 
(Ehteshami Bejnordi et al., 2017). Hence, this experiment has shown that deep learning algorithms 
could identify metastases in sentinel axillary lymph nodes slides with 100% sensitivity, whereas 40% 
of the slides without metastases could be identified as such. This approach can significantly reduce the 
workload of pathologists and improve the management decisions on whether or not to administer a 
therapy, perform a surgical intervention, etc. Overall, then, this interesting result shows the potential of 
AI applied in cancer imaging for detection of lymph node metastases in women with breast cancer to 
improve processes of diagnosis and therapy of this and other critical cancers (cf., Ehteshami Bejnordi 
et al., 2017).  
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 Statistical analyses of evolutionary trajectories of AI technology in cancer imaging (lung, breast 
and thyroid).  
 
Figure 3. Evolutionary trends of number of article about AI technology per different types of cancer 
(lung, breast, and thyroid) over 1996-2018 period. 
 
Table 2. Estimated relationships of AI in articles per different types of cancer on time  
(Exponential model, 1996-2018 period) 
Note:  Dependent variable: Number of articles about the terms Artificial intelligence per 
different types of cancer; explanatory variable is time; ***= p-value< .001 
 Lung 
cancer 
Breast 
cancer 
Thyroid 
cancer 
Constant 0 1.000E-013 1.000E-013 1.000E-013 
(St. Err.) (0.00) (0.00) (0.00) 
    
    
Coefficient 1 0.093*** 0.083*** 0.067*** 
(St. Err.) (0.008) (0.006) (0.008) 
    
    
F 127.46 186.63 72.34 
Sig.  0.001 0.001 0.001 
    
R2 adj.  0.85 0.89 0.76 
(St. Err. of the Estimate) (0.28) (0.21) (0.28) 
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Figure 4. Evolutionary trends of number of article about deep learning algorithms per different types of 
cancer (lung, breast, and thyroid) over 1996-2018 period.  
 
Table 3. Estimated relationships of deep learning articles per different types of cancer on time  
(Exponential model, 1996-2018 period) 
Note:  Dependent variable: Number of articles about the terms Deep Learning per 
different types of cancer; explanatory variable is time; ***= p-value< .001 
 Lung 
cancer 
Breast 
cancer 
Thyroid 
cancer 
Constant 0 1.000E-013 1.000E-013 1.000E-013 
(St. Err.) (0.00) (0.00) (0.00) 
    
    
Coefficient 1 0.091*** 0.094*** 0.082*** 
(St. Err.) (0.005) (0.005) (0.007) 
    
    
F 302.55 317.25 138.49 
Sig.  0.001 0.001 0.001 
    
R2 adj.  0.92 0.93 0.86 
(St. Err. of the Estimate) (0.18) (0.18) (0.23) 
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Figure 5. Exponential curves of the number of articles about deep learning per different types of cancer 
(lung, breast, thyroid) on time, 1996-2018 period  
 
Table 4 – Rates (per cent) of evolutionary pathways (based on exponential growth) of artificial 
intelligence and deep learning in lung, breast and thyroid cancer from 1996 to 2018 
Rates of growth 
Artificial 
Intelligence 
and 
lung  
cancer 
Artificial 
Intelligence 
and 
breast 
cancer 
Artificial 
Intelligence 
and 
thyroid 
cancer 
Deep 
learning 
and 
lung 
cancer 
Deep 
learning  
and 
breast 
cancer 
Deep 
learning  
and 
thyroid 
cancer 
r exponential 9.899 8.119 6.803 10.489 11.687 9.987 
 
Figures 3 - 4 show that the evolution of AI in oncology has exponential patterns of growth started in 
1990s and ongoing, with an acceleration mainly for lung cancer (cf., Fig. 5). Statistical analysis based 
on regression analysis shows that R2 adjusted of models indicates that more than 85% of variation in 
production of articles in AI per different types of cancer can be attributed (linearly) to the time as 
predictor (Tabb. 2-4). In particular, estimated relationships and exponential rates of growth suggest that 
AI in cancer imaging of breast and lung have a faster growth than thyroid cancer.  
A main finding of this study is the recognition that, since the late 1990s, the sharp increase of 
technological trajectories of AI technology applied in cancer imaging seems to be driven by high rates 
of mortality of some types of cancers (e.g., lung and breast) in order to find techniques for a more 
accurate detection, characterization and monitoring to apply efficiently anticancer therapies that 
increase the progression-free survival of patients: the so-called mortality-driven technological 
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trajectories in AI (cf., Coccia and Wang, 2014; Coccia, 2016). These ground-breaking technological 
trajectories of AI are paving new directions and clinical challenges, creating the foundations for a 
revolution in medicine that may lead to more effective diagnostic equipment in clinical settings in the 
not-too-distant future for a paradigm shift in clinical practice of pathology. 
Limitations 
The results and arguments of this study are of course tentative. In fact, the phenomenon is complex and 
analyses here are not sufficient to explain the pros and cons of the patterns of AI in cancer imaging, 
since we know that other things are often not equal over time and space. This study may form a ground 
work for development of more sophisticated studies and theoretical frameworks. Future efforts in this 
research field should provide more statistical evidence to substantiate the theoretical framework here. 
To reiterate, the study here is exploratory in nature and there is need for much more detailed research to 
shed further theoretical and empirical light on technological trajectories supporting the clinical 
challenges and applications of AI technology in cancer imaging. This analysis shows general pathways 
of the evolution of AI in oncology, however the evolution of AI technology in medicine is a non-trivial 
exercise because it depends on the behavior of other technologies and manifold factors of 
socioeconomic systems. In this context, Wright (1997, p. 1562) properly claims that: “In the world of 
technological change, bounded rationality is the rule.”  
Discussion and conclusion 
Bi Wenya et al. (2019) argue that cancer offers a unique context for medical decisions based on 
variegated forms of disease, individual condition of patients, their ability to receive treatment, and their 
responses to treatment (cf., Rosenberg, 1969; Arthur, 2009; McNerney et al., 2011). Clinical challenges 
are in the accurate detection, stage, type and sub-type of cancers. Radiographic evaluation of cancer 
most commonly relies upon visual analysis of imaging, the interpretations of which may be augmented 
by advanced computational analyses. The new technology of artificial intelligence (AI) can improve 
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the interpretation of cancer imaging by pathologists to detect volumetric delineation of tumors over 
time, mutations, and diffusion on other organs. AI may support the clinical process of interpretation of 
images to shift the clinical workflow of pathologists towards management decisions on whether or not 
to administer an intervention, and/or anticancer drugs, etc.  
In medicine, radiology, having converted to digital images about 30 years ago, is well-positioned to 
deploy AI for diagnostics. Several studies have shown considerable opportunity to support radiologists 
in evaluating a variety of scan types, including mammography for breast lesions, computed 
tomographic scans for pulmonary nodules and infections, and magnetic resonance images for brain 
tumors including the molecular classification of brain tumors. With conversion to digital images, 
radiology reduced costs eliminating film, chemicals, developers, and storage of the films. Moreover, 
radiology departments also solved problems related to loss of films and transport of films to where they 
are needed, for example, in operating rooms, emergency departments, and intensive care units. In short, 
digital images using computers have improved the quality, safety, and efficiency of radiologists in the 
management of disease. 
Pathology, by contrast to radiology, has been late to adopt digital imaging and computer-assisted 
diagnostic technologies. The emergence of AI in health care, the reduced costs of digital data, and the 
availability of usable digital images are now in alignment for digital pathology to succeed.  
However, there are some barriers to the technological diffusion of AI in some medical fields. A major 
unresolved issue is how AI will be implemented in routine clinical practice. Numerous intertwined 
problems will have to be addressed to overcome several significant obstacles for the diffusion of AI in 
pathology and other branches of medical science.  
Firstly, digital pathology based on AI may likely be costly at the initial phase of diffusion of this new 
technology owing to additional workflow, including personnel, AI must demonstrate improved 
efficiency, quality, and safety. These issues are the first and immediate barriers to a broad application 
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of AI in pathology and clinical practice. However, benefits will inevitably come from the use of AI 
with digital images and multiple data sets, for example, integrating genomic data and radiologic images 
to further enhance the value of combined data utilization for the overall health care system. Recent 
examples with skin lesions, diabetic retinopathy, and radiology detection have highlighted the potential 
that AI provides to aid clinicians to improve quality, safety and diagnosis (Gulshan et al., 2016; Esteva. 
et al. 2016)  
Secondly, the cost of new technological devices is an economic barrier. This cost is associated to the 
efficacy and efficiency of AI in pathology that have to be clearly demonstrated to government and 
third-party payers (e.g., insurance companies) developing reimbursement strategies. Although some 
reimbursement codes exist for computational analyses in the USA, they are not widely used and often 
are rejected. With US national health care reimbursement trends moving to quality and safety metrics, 
the recognition of AI technology as part of reimbursement strategies that reward value-based care, 
rather than fee for service value-based care, would provide important incentives to develop and 
implement validated algorithms of AI in clinical practice. 
Thirdly, the critical factor for AI technology is human capital and education that will be the greatest 
challenge and will require the longest period to address. AI and other computational methods must be 
integrated into all training programs of the schools of medicine worldwide. Future generations of 
pathologists and physicians must have technical skills comfortable to use digital images and other data 
in combination for accurate diagnosis.  
Overall, then, the promise of AI in health care is the delivery of improved quality and safety of care 
with the great potential of reducing the inequality in the access to healthcare sector between people 
within poor and rich countries. Put otherwise, AI technology in medicine can increase the 
democratization of the health care system, and it can potentially provide value in many economic 
sectors generating benefits for an industrial and corporate change based on this new technological 
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paradigm (cf., Coccia, 2010, 2014a). For instance, radiologists can now read imaging studies from 
anywhere in the world at their home institution/office, bringing expert care to parts of the world that 
previously had limited expertise. Pathology has the opportunity to do the same with digital imaging and 
AI combined with ICTs can permit rapid and accurate local care, also in developing countries where 
there is a high burden of diseases and low medical equipment. 
To conclude, deep learning and in general AI have the opportunity to assist pathologists and physicians 
by improving the efficiency of their work, standardizing quality, and providing better prognostication. 
Although workflow of pathologists and other physicians is likely to change with AI technology, the 
contributions of pathologists, and in general of humans, to patient care will continue to be critically 
important to treat diseases. Finally, most studies evaluating AI in oncology and other branches of 
medicinal sciences to date have not been vigorously validated for reproducibility and generalizability 
of results. Further research is necessary in applied research to determine the feasibility of applying AI 
in the clinical setting and to determine whether use of the AI could lead to improved care and outcomes 
compared with current technologies and medical assessments. Overall, then, the technological change 
based on technological paradigm shift of AI in medicine seems to be started to push regional and 
national economies in the next future. 
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